


## Edoxaban tosylate monohydrate

<b>Cat. No.:</b>	HY-10264B
<b>CAS No.:</b>	1229194-11-9
<b>Molecular Formula:</b>	C <sub>31</sub> H <sub>40</sub> ClN <sub>7</sub> O <sub>8</sub> S <sub>2</sub>
<b>Molecular Weight:</b>	738.27
<b>Target:</b>	Factor Xa; Thrombin
<b>Pathway:</b>	Metabolic Enzyme/Protease
<b>Storage:</b>	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 50 mg/mL (67.73 mM; Need ultrasonic)					
	H <sub>2</sub> O : 1 mg/mL (1.35 mM; Need ultrasonic)					
	<b>Preparing Stock Solutions</b>	<b>Solvent</b>	<b>Mass</b>	<b>1 mg</b>	<b>5 mg</b>	<b>10 mg</b>
		<b>Concentration</b>				
		<b>1 mM</b>		1.3545 mL	6.7726 mL	13.5452 mL
<b>5 mM</b>			0.2709 mL	1.3545 mL	2.7090 mL	
	<b>10 mM</b>		0.1355 mL	0.6773 mL	1.3545 mL	
Please refer to the solubility information to select the appropriate solvent.						
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (3.39 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (3.39 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (3.39 mM); Clear solution					

### BIOLOGICAL ACTIVITY

<b>Description</b>	Edoxaban (DU-176b) monohydrate is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with K <sub>i</sub> s of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban monohydrate exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban monohydrate can be used for preventing thromboembolic disease research <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	IC <sub>50</sub> : 2.90 μM (platelet aggregation), K <sub>i</sub> : 0.561 nM (free human FXa), 2.98 nM (prothrombinase), 0.715 nM (cynomolgus monkey FXa), 0.457 nM (rabbit FXa) <sup>[1]</sup>

<b>In Vitro</b>	<p>Edoxaban monohydrate (1, 1 and 5 minutes respectively) prolongs PT, TT and APTT of human plasma in a concentration-dependent manner<sup>[1]</sup>.</p> <p>?Edoxaban monohydrate inhibits thrombin-induced platelet aggregation, with an IC<sub>50</sub> of 2.90 μM<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay<sup>[1]</sup></p>	
	Cell Line:	Human, rat, cynomolgus monkey and rabbit plasma; Human platelet
	Concentration:	
	Incubation Time:	1 and 5 minutes
	Result:	Antithrombin.
<b>In Vivo</b>	<p>Edoxaban monohydrate (0.5, 2.5 and 12.5 mg/kg; p.o.; once) significantly and dose-dependently reduces the thrombus formation and prolongs PT<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>	
	Animal Model:	Male Slc: Wistar rats (210-240 g); Male New Zealand White rabbits(2.5-3.5 kg) (Both are venous stasis thrombosis model) <sup>[1]</sup> .
	Dosage:	0.5, 2.5 and 12.5 mg/kg
	Administration:	Oral administration; once
	Result:	Inhibited exogenous FXa activity. Antithrombotic.

## CUSTOMER VALIDATION

- Molecules. 2023 Feb 28.
- Thromb Res. 2021 Jan;197:141-143.
- Authorea. 2023 Apr 17.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

[1]. Furugohri T, et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost. 2008 Sep;6(9):1542-9.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA